BIOCON

Key Financials and Performance (Q1 FY26)

Biocon recently announced its Q1 FY26 results, which provide critical insights into its performance. Share Price: As of August 8, 2025, the share price on the NSE is approximately ₹350.25. The stock has been volatile, with a 52-week high of ₹406 and a 52-week low of ₹291. Market Capitalization: Approximately ₹48,746 Crore. Revenue from Operations: The consolidated operating revenue for Q1 FY26 grew by 15% year-over-year (YoY) to ₹3,942 Crore, driven by strong performances in the Biosimilars and Research Services segments. Profit After Tax (PAT): The reported consolidated PAT for Q1 FY26 was ₹31 Crore, a sharp 95% decline YoY. It is crucial to note that the company had a one-time divestment gain in the same quarter last year, which created a high base for comparison. On a like-for-like basis (excluding the exceptional item), the net profit showed growth. EBITDA: Consolidated core EBITDA (excluding forex, R&D, and other non-core items) for Q1 FY26 was ₹1,003 Crore, an 11% YoY growth. The core EBITDA margin stood at 25%. Debt-to-Equity Ratio: The company has a debt-to-equity ratio of around 0.85, indicating a moderate level of leverage. P/E Ratio: The trailing twelve-month (TTM) P/E ratio is around 41.39, which suggests the market has high growth expectations from the company. Recent Developments and Strategic Initiatives Biosimilars and Generics: The Biosimilars business saw an 18% YoY revenue increase in Q1 FY26, driven by robust demand. The Generics business also grew by 6%. Regulatory Approvals and Launches: Biocon Biologics received a key regulatory approval for Insulin Aspart in the U.S. and launched Yesafili™ (aflibercept) in Canada, its tenth biosimilar globally. These are significant milestones that can drive future revenue growth.